Laurus Labs

BSE, Hitachi Energy, GE Vernova, Syrma SGS, Force Motors, HBL Engineering and Laurus Labs have gained more than 50% each after these companies reported over 50% growth in profit in Q1 and Q2 of FY26.

Among the companies trading ex-dividend on Friday, Coforge has declared an interim dividend of ₹4 per share, with the record date set for the same day

HDFC Bank (HDFCB) reported a steady Q2FY26, with profit rising 11 per cent Y-o-Y to ₹186.4 billion, aided by healthy NII of ₹315.5 billion and strong treasury gains of ₹23.9 billion

Thus far in the month of October 2025, Laurus Labs has outperformed the market by surging 14 per cent.

Laurus Labs reported a strong Q2 FY26 performance, with consolidated net profit soaring multifold to ₹194.97 crore, compared with ₹19.78 crore in Q2 FY25

Q2FY26 company results: Many firms including PTC India Financial Services, Tata Teleservices, Jumbo Bag and Vardhman Textiles are also to release their July-September quarter earnings reports today

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

At 11:29 AM, Laurus Labs' stock was quoting 2 per cent higher at ₹943.15 on the BSE, commanding an m-cap of ₹50,913 crore, exchange data shows

Thus far in September, the stock price of Laurus Labs has rallied 6 per cent, as compared to a 1.5 per cent rise in the BSE Sensex and BSE Healthcare index

Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details

Laurus stock price outlook: Given the higher-margin profile of CDMO and operating leverage as new manufacturing assets ramp, brokerage firms expect sustained margin expansion.

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Scale-up of the CDMO segment in FY26, is expected to contribute meaningfully to revenue growth and margin expansion, aided by better capacity utilisation and operational execution, CareEdge Ratings.

Laurus Labs management sees a clear pathway for further margin expansion as the company continue delivering on mid-late phase projects, ramping up new assets, and better asset utilisation.

Stocks to buy: Analyst at Angel One recommends Ashok Leyland, Grasim and one other stock; Check target price, stop loss here

Laurus Labs stock was quoting at ₹618.50, down 4.18 per cent from the previous session's closing price of ₹645.50

Drug firm Laurus Labs on Thursday said its consolidated profit increased three-fold to Rs 234 crore for the March quarter, driven by strong sales. The Hyderabad-based company reported a net profit of Rs 76 crore for the same quarter of FY24. Revenue increased to Rs 1,720 crore for the fourth quarter as compared with Rs 1,440 crore in the year-ago period, Laurus Labs said in a regulatory filing. For FY25, the company said its profit rose to Rs 358 crore as against Rs 161 crore in the 2023-24 fiscal year, it added. Revenue increased to Rs 5,554 crore in last fiscal year as compared with Rs 5,041 crore in the 2023-24 financial year. "We delivered very good Q4 results and continued our transformative progress, reflecting robust demand for our CDMO offerings and meeting complex customer needs," Laurus Labs Founder & CEO Satyanarayana Chava said. The company is deepening its cooperation with major clients, and augmenting it with promising BD and capacity creation, he added. "Our ...

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Trump tariffs: Blue Jet Healthcare, Aarti Pharmalabs, Marksans Pharma, Ipca, Wockhardt, Ami Organics, Biocon, Piramal Pharma, Lupin, Laurus Labs and Gland Pharma dropped in the range of 3% to 10%